Takeda Pharmaceutical Company Limited





Market Closed - Japan Exchange 02:00:00 2024-06-24 EDT 5-day change 1st Jan Change
4,095 JPY +1.66% Intraday chart for Takeda Pharmaceutical Company Limited -1.13% +1.01%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Hutchmed China notes Takeda obtains EU approval for Fruzaqla AN
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators MT
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment MT
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare CI
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment MT
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib) CI
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment DJ
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer CI
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India CI
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting CI
Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback DJ
Sector Update: Health Care Stocks Decline Premarket Monday MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies DJ
Takeda's seizure drug fails to meet main goal in late-stage studies RE
Chart Takeda Pharmaceutical Company Limited
More charts
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
4,095 JPY
Average target price
4,744 JPY
Spread / Average Target
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. Takeda Pharmaceutical's Attributable Profit Falls 55% in Fiscal 2024